Amylyx Pharmaceuticals, Inc. Operating Cash Flow
Amylyx Pharmaceuticals, Inc. (AMLX) reported Operating Cash Flow of -$68.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$31.42M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$36.88M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$27.90M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$30.37M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$123.34M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$167.65M, a 1506.55% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $11.92M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$179.87M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$68.31M 10-Q · filed 2026-08-06 | -$96.21M derived: sum of 3 quarters · filed 2026-08-06 | -$126.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$36.88M 10-Q · filed 2026-05-07 | -$64.78M derived: sum of 2 quarters · filed 2026-05-07 | -$95.15M derived: sum of 3 quarters · filed 2026-05-07 | -$120.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$27.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$58.27M derived: sum of 2 quarters · filed 2026-03-03 | -$83.52M derived: sum of 3 quarters · filed 2026-08-06 | -$123.34M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$30.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$55.62M derived: sum of 2 quarters · filed 2026-08-06 | -$95.44M 10-Q · filed 2025-11-06 | -$154.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$25.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$65.07M 10-Q · filed 2026-08-06 | -$124.08M derived: sum of 3 quarters · filed 2026-08-06 | -$165.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$39.82M 10-Q · filed 2026-05-07 | -$98.83M derived: sum of 2 quarters · filed 2026-05-07 | -$140.40M derived: sum of 3 quarters · filed 2026-05-07 | -$206.98M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$59.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$100.58M derived: sum of 2 quarters · filed 2026-03-03 | -$167.16M derived: sum of 3 quarters · filed 2026-03-03 | -$167.65M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$41.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$108.15M derived: sum of 2 quarters · filed 2025-11-06 | -$108.64M 10-Q · filed 2025-11-06 | -$95.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$66.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$67.07M 10-Q · filed 2025-08-07 | -$53.52M derived: sum of 3 quarters · filed 2025-08-07 | -$58.69M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$489.00K 10-Q · filed 2025-05-08 | $13.06M derived: sum of 2 quarters · filed 2025-05-08 | $7.89M derived: sum of 3 quarters · filed 2025-05-08 | $16.50M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $13.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $8.38M derived: sum of 2 quarters · filed 2025-03-04 | $16.99M derived: sum of 3 quarters · filed 2025-03-04 | $11.92M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.44M derived: sum of 2 quarters · filed 2024-11-07 | -$1.63M 10-Q · filed 2024-11-07 | -$51.33M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $8.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.54M 10-Q · filed 2024-08-08 | -$46.16M derived: sum of 3 quarters · filed 2024-08-08 | -$89.24M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$5.07M 10-Q · filed 2024-05-09 | -$54.77M derived: sum of 2 quarters · filed 2024-05-09 | -$97.85M derived: sum of 3 quarters · filed 2024-05-09 | -$144.31M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$49.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$92.78M derived: sum of 2 quarters · filed 2024-02-22 | -$139.24M derived: sum of 3 quarters · filed 2024-02-22 | -$179.87M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$43.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$89.54M derived: sum of 2 quarters · filed 2023-11-09 | -$130.17M 10-Q · filed 2023-11-09 | -$158.42M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$46.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$87.10M 10-Q · filed 2023-08-10 | -$115.34M derived: sum of 3 quarters · filed 2024-02-22 | -$136.21M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$40.63M 10-Q · filed 2023-05-11 | -$68.88M derived: sum of 2 quarters · filed 2024-02-22 | -$89.74M derived: sum of 3 quarters · filed 2024-02-22 | -$102.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$28.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$49.11M derived: sum of 2 quarters · filed 2024-02-22 | -$62.16M derived: sum of 3 quarters · filed 2024-02-22 | -$74.80M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$20.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$33.91M derived: sum of 2 quarters · filed 2022-11-10 | -$46.55M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$13.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$25.69M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$12.64M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |